We are live on ! Find out more
SEC

Seven Eight Capital Portfolio holdings

AUM $1.11B
1-Year Est. Return 29.48%
This Fund
S&P 500
This Quarter Est. Return
-6.56%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$855M
AUM Growth
+$250M
Cap. Flow
+$327M
Cap. Flow %
38.29%
Top 10 Hldgs %
13.1%
Holding
788
New
316
Increased
155
Reduced
106
Closed
211

Top Buys

Rank Stock Value
1
EW icon
Edwards Lifesciences
EW
+$13.6M
2
MRK icon
Merck
MRK
+$12.5M
3
ISRG icon
Intuitive Surgical
ISRG
+$11.1M
4
DOCU
DocuSign
DOCU
+$10.9M
5
PODD icon
Insulet
PODD
+$10.8M

Top Sells

Rank Stock Value
1
NDAQ icon
Nasdaq
NDAQ
+$7.26M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.86M
3
INCY icon
Incyte
INCY
+$6.31M
4
FIS icon
Fidelity National Information Services
FIS
+$5.73M
5
ABBV icon
AbbVie
ABBV
+$4.95M

Sector Composition

Rank Sector Weight
1 Technology 20.41%
2 Consumer Discretionary 17.68%
3 Healthcare 16.13%
4 Industrials 12.13%
5 Financials 8.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNH
776
CNH Industrial
CNH
$12.7B
– –
-61,360
Closed -$884K
PENG
777
Penguin Solutions Inc
PENG
$2.7B
– –
-49,679
Closed -$1.44M
FLG
778
Flagstar Bank National Association
FLG
$5.93B
– –
-12,343
Closed -$416K
LUCK
779
Lucky Strike Entertainment
LUCK
$914M
– –
-38,741
Closed -$451K
BERY
780
DELISTED
Berry Global Group, Inc.
BERY
– –
-17,204
Closed -$1.02M
PDCO
781
DELISTED
Patterson Companies, Inc.
PDCO
– –
-28,883
Closed -$961K
ITCI
782
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-6,625
Closed -$419K
RVNC
783
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-70,697
Closed -$1.79M
AXNX
784
DELISTED
Axonics, Inc. Common Stock
AXNX
– –
-7,830
Closed -$395K
SQSP
785
DELISTED
Squarespace, Inc.
SQSP
– –
-16,376
Closed -$516K
ABCM
786
DELISTED
Abcam PLC
ABCM
– –
-59,330
Closed -$1.45M
NEX
787
DELISTED
NexTier Oilfield Solutions Inc.
NEX
– –
-35,196
Closed -$315K
PDCE
788
DELISTED
PDC Energy, Inc.
PDCE
– –
-17,982
Closed -$1.28M
28 29 30 31
32

Similar funds

PP
Pegasus Partners Mequon, Wisconsin $1.07B AUM 32.32% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return
CAM
ClariVest Asset Management San Diego, California $980M AUM 60.89% 1-Year Est. Return
D
Diversified Wilmington, Delaware $911M AUM 31% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
FTIS
First Trust Investment Solutions Naples, Florida $888M AUM 34.3% 1-Year Est. Return
AIA
Alera Investment Advisors Deerfield, Illinois $851M AUM 29.76% 1-Year Est. Return

Seven Eight Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Seven Eight Capital held 788 positions worth $855M, up 41% from $605M the previous quarter. Its ten largest holdings account for 13% of the portfolio.

Seven Eight Capital deployed $327M of net new capital in Q3 2023, opening 316 new positions and adding to 155 existing holdings. Its largest new stake was Merck: 115,677 shares worth $11.9M.

By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $6.86M trimmed.

  • Seven Eight Capital's largest Q3 2023 buy was Merck: 115,677 shares worth $11.9M.
  • Seven Eight Capital added most to Edwards Lifesciences in Q3 2023, an estimated $13.6M increase.
  • Seven Eight Capital's biggest Q3 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $6.86M.
  • Seven Eight Capital fully exited Nasdaq in Q3 2023, selling an estimated $7.26M.
  • Seven Eight Capital's ten largest holdings make up 13% of its $855M portfolio in Q3 2023.
  • Seven Eight Capital opened 316 new positions and closed 211 in Q3 2023.
  • Seven Eight Capital's portfolio value rose 41% quarter-over-quarter to $855M.

Based on Seven Eight Capital's 13F filing for Q3 2023, filed 14 Nov 2023.